ABSTRACT
Aim: This study aims to assess the outcome of transarterial chemoembolization (TACE) and sorafenib in the treatment ofadvanced stage of hepatocellular carcinoma (HCC).Materials and Methods: The longitudinal analysis of the data was approved by the institutional ethical committee and properinformed consent was taken from the study population. Advanced-stage HCC was defined according to Barcelona clinic livercancer staging classification (Child-Pugh Class A or B, Eastern Cooperative Oncology Group performance status of 1–2, and/or macrovascular invasion or extrahepatic metastasis). A total number of 22 patients of advanced-stage HCC were treatedwith TACE (n = 11) and sorafenib (n = 11) between the period of July 2017 and September 2018. Modified response evaluationcriteria in solid tumors (mRECIST) were used to evaluate the outcome in all patients.Results: There was no significant difference between the tumor characteristics (size and number of the lesion, portal veininvasion, and metastases) in the study groups. Both sorafenib and TACE would result in stable response in majority of thepatients using mRECIST with no significant difference in the overall survival period between these two treatment modalities.Conclusion: TACE is similar to sorafenib in terms of outcome in advanced-stage HCC using mRECIST. Thus, TACE can be consideredas an effective treatment modality in advanced-stage HCC; however, further studies are required to firmly establish this clause.